Alzheimer's trial screening data links high amyloid levels with early stage disease

With completion expected in late 2022, the A4 study is an ongoing prevention trial launched in 2014 to test whether the drug solanezumab, a monoclonal antibody, could slow cognitive decline associated with elevated brain amyloid if started before clinical symptoms appear. Amyloid, long considered a hallmark of Alzheimer's disease, has been the target of therapies in clinical trials in people who already show symptoms of the disease.

"A major issue for amyloid-targeting Alzheimer's disease clinical trials, and one that is being addressed with the A4 study, is that previous trials may have been intervening too late in the disease process to be effective," said NIA Director, Richard J. Hodes, M.D. "A4 is pioneering in the field because it targets amyloid accumulation in older adults at risk for developing dementia before the onset of symptoms."

The A4 study team was looking for cognitively normal participants with high levels of amyloid. They started by pre-screening more than 15,000 people who expressed interest in the trial. Of those 15,000, the researchers brought in 6,763 clinical trial volunteers for cognitive testing, clinical assessments and genotyping. After excluding 2,277 participants for cognitive and/or medical reasons, researchers used amyloid positron emission tomography (PET) imaging with 4,486 participants to measure amyloid accumulation in the brain. The PET imaging revealed 1,323 with elevated amyloid levels who were eligible to continue in the A4 study.

"In 2014, A4 was a first-of-its-kind study because it used amyloid PET to identify cognitively normal people with high levels of brain amyloid," said Laurie Ryan, Ph.D., chief of the Dementias of Aging branch in NIA's Division of Neuroscience. "Before the availability of amyloid PET, other amyloid-targeting clinical trials may have been testing therapies in some people who didn't have amyloid."

Writing for the A4 study team, lead author Reisa A. Sperling, M.D., at Brigham and Women's Hospital and Harvard Medical School, Boston, noted in the paper that the screening data of all 4,486 participants who had PET imaging is now available to the research community. This new data will help improve efficiency of screening and enrollment of other trials designed to prevent Alzheimer's in people without symptoms.

"A4 demonstrates that prevention trials can enroll high risk individuals -- people with biomarkers for Alzheimer's who are cognitively normal," said Ryan, adding, "Ultimately, precision medicine approaches will be essential."

"Alzheimer's disease is never going to have a one-size-fits-all treatment," she said. "We're likely to need different treatments, even combinations of therapies, for different individuals based on their risk factors."

NIA's diverse Alzheimer's disease and related dementias research portfolio includes about 230 clinical trials. Of these, more than 100 are focused on non-pharmacological interventions, including but not limited to diet, exercise and cognitive training. Of the current 46 pharmacological trials supported by NIA, most investigate targets other than amyloid, such as neuroprotection and inflammation.

The research in this study is funded by NIH grants U19AG010483 and R01AG063689. Clinical trial number NCT02008357.